Atlas market file · Equity · United States
Galectin Therapeutics IncGALT
- Last close
- 3.22
- Change
- +4.21%
- 96-bar range
- 2.03 – 5.55
- As of
- 6 Aug 2026
Galectin Therapeutics Inc is a pharmaceutical preparations issuer listed as GALT on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
GALT
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+39.39% over the window).
Source rail: Yahoo Finance chart API (GALT). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for GALT. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
GALT public profile
Pharmaceutical preparations issuer. Galectin Therapeutics Inc is connected to current market context, cited company sources and its retained research file.
Galectin Therapeutics Inc trades as GALT on NASDAQ. Galectin Therapeutics Inc (GALT) has a latest verified close of 3.22, up 4.21%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files GALT under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Galectin Therapeutics Inc today
Galectin Therapeutics Inc. is a company that seems to be navigating a complex environment of research and development, with a focus on galectin-3 inhibition and alternative drug delivery methods.
The company's financials, however, paint a somewhat different picture, with a net loss of $5.0 million and operating income loss of $4.1 million in the period ending 2026-03-31.
According to their latest 10-Q filing, the company has $14.1 million in cash and cash equivalents, and has entered into an At Market Issuance Sales Agreement, which allows them to issue and sell shares of common stock.
The company's research and development expenses were $2.2 million, and they've established a discovery program developing small molecules that inhibit galectin-3.
It's worth noting that the company's liabilities are significant, at $146.0 million, and their stockholders' equity attributable to parent is $-132.0 million.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
GALT technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on GALT
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep GALT research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
GALT FAQ
What is Galectin Therapeutics Inc (GALT)?Galectin Therapeutics Inc (GALT) has a latest verified close of 3.22, up 4.21%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Galectin Therapeutics Inc (GALT) has a latest verified close of 3.22, up 4.21%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for GALT?Galectin Therapeutics Inc (GALT) has a latest verified close of 3.22, up 4.21%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Galectin Therapeutics Inc (GALT) has a latest verified close of 3.22, up 4.21%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files GALT under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the GALT page updated?The GALT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The GALT public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for GALT?The GALT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:GALT. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The GALT file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:GALT. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on GALT?Yes. The workstation can open GALT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open GALT, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this GALT page investment advice?No. The GALT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The GALT page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →